Thymosin Alpha-1: Immune Research Evidence

Summary

Thymosin alpha-1 is a 28–amino-acid peptide derived from prothymosin alpha, produced by the thymus and involved in T-cell maturation. Of the peptides covered in this hub it has the most extensive human trial record — it is approved in around thirty countries for hepatitis B and as a vaccine adjuvant — but it is not approved in the US, EU or UK.

Last reviewed 2026-09-01

What it is

Thymosin alpha-1 (Tα1) is a 28-residue acetylated peptide cleaved from prothymosin alpha. It is marketed in some jurisdictions as thymalfasin, brand name Zadaxin.

Isolated from thymosin fraction 5 in 1972 by Allan Goldstein's group, it was among the first thymic peptides to be characterised and reached clinical development in the 1990s.

Endogenous, produced primarily by thymic epithelial cells; the therapeutic product is synthetic.

Thymic involution with age is a central feature of immunosenescence, and Tα1 offered a defined molecule to test whether thymic signalling could be supplemented.

How it works

In plain terms

Thymosin alpha-1 helps immune cells mature and become better at recognising threats, and appears to tune the immune response rather than simply amplifying it.

Technical detail

Tα1 signals through Toll-like receptors, primarily TLR2 and TLR9, on dendritic cells and monocytes, leading to MyD88-dependent activation and altered cytokine profiles. Reported effects include enhanced dendritic cell maturation, increased IL-2 and IFN-γ production, restoration of T-cell counts in lymphopenic states, increased MHC class I expression on target cells, and modulation of regulatory T-cell activity. The bidirectional nature of the response — enhancing depressed immunity and dampening excessive inflammation — is a recurring theme in the literature.

Pathways involved

TLR2 / TLR9 → MyD88 signalling in dendritic cells
T-cell maturation and CD4/CD8 restoration
IL-2 and IFN-γ production
MHC class I upregulation
Regulatory T-cell modulation

Current research

Laboratory research

Dendritic cell and T-cell cultures show maturation markers and cytokine shifts consistent with TLR-mediated signalling.

Animal research

Infection and sepsis models report improved survival and restored lymphocyte counts; tumour models report enhanced immune-mediated control, generally in combination with other agents.

Human research

Randomised trials exist in chronic hepatitis B, hepatitis C combination therapy, severe sepsis and as a vaccine adjuvant in elderly and dialysis populations. Results are variable: hepatitis B data supported approval in several countries, while large sepsis trials produced inconsistent mortality findings. It has been used in oncology supportive-care settings in some jurisdictions.

Ongoing research

Immunomodulation in sepsis and in immunosenescence remains an active clinical research area.

What is being investigated

Chronic hepatitis B and C treatment support
Sepsis and immunoparalysis
Vaccine response in elderly and dialysis patients
Immune support in oncology settings
Age-related immune decline (immunosenescence)

These are research directions reported in the literature, not established effects or recommendations.

Risks, limitations and unknowns

Read this section before the rest

Not approved in the US, EU or UK, despite approval in roughly thirty other countries
Trial results are inconsistent across indications, particularly in sepsis
Immunomodulation carries theoretical autoimmune risk; use alongside immunosuppressive therapy is not established
Most positive data comes from patient populations, not healthy individuals — extrapolation is unwarranted
Injection-site reactions are the most commonly reported adverse effect

Evidence ratings

Laboratory studies

Strong

TLR signalling mechanism well documented.

Animal studies

Strong

Consistent infection-model survival findings.

Human studies

Moderate

Multiple randomised trials; results vary by indication.

Long-term safety

Moderate

Decades of marketed use in some countries; healthy-population data absent.

References

[1]Thymosin alpha-1 — indexed literature — PubMed, 1972–present
[2]Thymosin alpha-1 hepatitis B trials — PubMed, 1995–present
[3]Registered trials — thymalfasin — ClinicalTrials.gov, current
Reference links open searches and records on PubMed and ClinicalTrials.gov so that every statement above can be traced to primary literature.

Frequently asked questions

What is thymosin alpha-1?+

A 28–amino-acid peptide derived from prothymosin alpha that participates in T-cell maturation and immune signalling.

Is thymosin alpha-1 approved?+

It is approved in roughly thirty countries, largely for chronic hepatitis B and as a vaccine adjuvant, but not in the US, EU or UK.

How does thymosin alpha-1 work?+

Mainly through TLR2 and TLR9 signalling on dendritic cells, promoting maturation and shifting cytokine output toward an effective adaptive response.

Is thymosin alpha-1 the same as TB-500?+

No. TB-500 relates to thymosin beta-4, a structurally and functionally unrelated molecule despite the shared 'thymosin' naming from the original thymic extract.

What is Zadaxin?+

The brand name for synthetic thymosin alpha-1 (thymalfasin) marketed in jurisdictions where it is approved.

Does it help healthy immune systems?+

No evidence supports that. Trials studied patients with hepatitis, sepsis or poor vaccine response, not healthy individuals.

Was thymosin alpha-1 studied during COVID-19?+

Yes, in observational and small trial settings in China and Italy, with mixed and largely inconclusive results.

What are the main side effects?+

Injection-site reactions are most common in trials; systemic adverse events have generally been infrequent.

Continue your research

What Is TB-500?

Different molecule, similar name

Chronic inflammation

Peptide Research hub